gilead report surpris descovi prep
updat forecast estim oct
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim oct
price data oct
rate updat oct
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
gilead gener stellar profit margin hiv hcv
portfolio requir small salesforc inexpens
manufactur think firm portfolio pipelin support
wide moat gilead need hcv market stabil strong
continu innov hiv solid pipelin data smart futur
acquisit return growth
gilead tenofovir tdf molecul -- viread truvada older
single-tablet regimen -- histor form heart firm
billion hiv franchis combo pill offer conveni
afford patient less like miss dose develop
drug resist need make one co-payment
newest combo pill -- replac tdf taf -- reduc bone
kidney safeti issu see rapid uptak gilead biggest
competit threat hiv glaxo triumeq saw rapid growth
glaxo launch two-drug regimen base
integras inhibitor tivicay juluca dovato
odefsey descovi biktarvi launch push
patent protect late boost gilead
sovaldi harvoni combin sovaldi ledipasvir
peak billion sale howev demand
shrink patient cure competit
merck led sever round signific
price-discount expect gilead share
billion-plu market long term
gilead build pipelin outsid hiv hcv need
acquisit like kite car-t therapi yescarta see
strong growth gilead first cancer drug zydelig launch
limit safeti concern optimist
galapago collabor lead nash program selonsertib
recent fail phase trial gilead on-going
therapi
mechan nash
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
develop market therapi treat life-threaten
infecti diseas core portfolio focus hiv
hepat acquisit coru pharma myogen cv
therapeut arresto bioscienc calistoga broaden focu
includ pulmonari cardiovascular diseas cancer gilead
acquisit pharmasset brought right hepat drug sovaldi
also part combin drug harvoni kite acquisit boost
gilead exposur cell therapi oncolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
filgotinib launch catalyst oct
maintain per share fair valu estim
gilead follow line third quarter remain
bullish uptak descovi hiv prophylaxi well
long-term potenti immunolog drug filgotinib
rheumatoid arthriti launch indic
ulcer coliti data strength gilead hiv
portfolio led hiv sale growth launch
taf-bas hiv treatment prophylaxi regimen
continu support share gain competitor like glaxo
filgotinib file regul europ
japan file come later year think
drug track late launch
differenti safeti efficaci profil although class-
relat black box warn relat thrombosi like
share remain under-valued expect two
product key improv investor sentiment gilead
wide moat root strong virolog franchis
also support pipelin progress immunolog
said expect continu under-perform cell
therapi hepat nash remain wild card
conserv expect follow
cell therapi yescarta consist long-term
conserv expect gilead car-t franchis due
competit car-t therapi clinic trial
well roch newly-approv therapi polivi
addit declin hepat franchis sale
match estim although expect price pressur
share loss lessen beyond gilead expect
phase data two-drug nash combin end
year although model sale nash
gilead think potenti efficaci could also
come in-progress combin novo nordisk
diabet therapi semaglutid data expect second
half
rais fair valu estim per share
increas biktarvi sale assumpt
follow rapid launch partli counter lower sale
older regimen like genvoya atripla also
increas forecast filgotinib higher
probabl approv rheumatoid arthriti
still assum gilead hcv busi fall
billion annual declin stabil around
think gilead hiv/hbv franchis peak billion
 gener competit lead
high-single-digit annual headwind begin
assum taf-bas combin regimen
biktarvi genvoya descovi odefsey help off-set
declin gilead could see mid-single-digit patient
loss annual begin still view
stribild complera gener strong
competit taf-bas regimen particularli outsid
overal forecast sale growth non-gaap
earn growth sovaldi harvoni high
gross margin strong oper leverag lower tax rate
led oper margin shrink
revenu think margin stay go
forward assum cost-cut help off-set
includ billion sale yescarta
annual sale stabil around level usag expand
second-lin dlbcl therapi form blood
cancer competit landscap get tougher
assum cost capit gilead rate
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
also use slightli higher earn growth rate stage
ii model result fair valu
estim per share
pessimist scenario assum complera
stribild next-gener taf-bas regimen like
genvoya biktarvi unabl gain signific share
hiv market lack perceiv efficaci
safeti conveni benefit compar older
regimen glaxo doublet regimen hiv franchis sale
peak billion less uptak newer regimen
potenti price pressur gilead fall
averag annual assum addit price
competit hepat market also use
earn growth rate stage ii model
patent protect newer hiv regimen gilead
continu domin hepat market
enough ensur strong return next coupl
decad gilead expertis infecti diseas
single-pil formul part research
develop strategi see one strongest
intang asset support firm wide moat
gilead moat form leadership posit
treatment hiv patent product form
backbon today treatment regimen despit numer
competitor compani establish lead market
share spectacular profit conveni
effect safe treatment gilead serv treat
hiv patient unit state manag done
excel job maxim sale tdf molecul
present viread truvada atripla complera
stribild said key patent begin expir
europ next-gener product could struggl
provid suffici differenti reimburs
systemat risk surround gilead share averag
assum cost equiti align capit cost
assumpt return equiti investor like
demand long run also assum pre-tax
cost debt reflect normal long-term rate
gilead portfolio divers hiv focu
expand exposur hepat cancer market
still think firm warrant medium uncertainti
rate owe volatil hepat market demand
price well firm increas relianc
abil success refresh hiv busi newer
product hcv revenu declin
bullish scenario expect gilead achiev stronger
convers newer hiv product stronger
hepat price power scenario assum hiv
franchis sale peak billion follow
mid-single-digit averag annual declin face
 hepat market bull-cas scenario
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
key market put pressur hiv franchis
howev think firm shown translat
extens understand drug discoveri
develop process hiv new therapeut area
allow achiev wide-moat statu despit initi
critic high price gilead paid pharmasset
earli billion acquisit gave gilead
valuabl hepat drug industri also
demonstr firm abil recogn potenti
uniqu natur sovaldi safeti efficaci profil
compar toxic nucleotid analog think
firm experi anoth nucleotid analog tenofovir
key ingredi gilead hiv combin regimen
probabl contribut recognit sovaldi valu
earli stage develop
molecul sovaldi harvoni redefin gilead
powerhous broader infecti diseas market
gilead lead way all-or treatment
hepat market multi-billion-dollar product
think low resist potenti pan-genotyp
efficaci gilead regimen allow firm retain
close global hcv market long run
despit competit merck
product platform reflect grow record recogn
potenti infecti diseas discoveri
foundat hiv drug tenofovir deal brought right
emtricitabin anoth ingredi gilead
combin regimen elvitegravir integras inhibitor
stribild sovaldi gilead oncolog pipelin also
grow advanc receiv boost
recent acquisit kite includ car-t cell therapi
yescarta think smart acquisit potenti
futur combin regimen hematolog oncolog
immunolog nash diversifi firm
strengthen intang asset howev think
gilead hiv-rel patent exposur price volum
headwind hepat market prevent moat
expand
firm acquisit strategi could serv well
oncolog immunolog follow sever year
smaller acquisit partnership gilead first
launch safeti risk limit usag
later line therapi howev oncolog drug
safer dose zydelig combin therapi still
test sever potenti
indic well yescarta acquir kite pharma
octob launch diffus larg b-cell
lymphoma think gilead histori smart clinic
trial design market expertis could boost launch
speed
long-term potenti kite portfolio
acquisit arresto nimbu apollo well
licens deal phenex given gilead sever
differ mechan treat nash although
selonsertib recent fail phase studi key
combin data read end
gilead product biolog firm
vulner gener version mani older hiv
product within five year howev newer hiv regimen
seen strong launch improv kidney bone
safeti profil taf tdf support genvoya
record fastest hiv combin pill sale ramp
gilead latest regimen biktarvi contain integras
requir booster rapidli becam prefer
regimen patent protect gilead
retain virtual econom behind hiv sale
newest combin pill rather share
partner complera johnson johnson
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
atripla bristol-my squibb benefit firm return
invest capit
gilead also face strong competit hiv still see
best posit field approv glaxo
integras inhibitor tivicay combin tablet triumeq
epzicom/tivicay led gilead market share declin
glaxo gilead appear gain
share hiv player merck bristol
lack combin pill expect gilead biktarvi
glaxo juluca approv dovato approv
continu domin market
gilead pipelin continu sale hiv beyond first
wave patent expir need counter declin
hcv tough year hcv
sale declin declin
declin brought larger hit demand falter
launch next-gener product think
see declin assum
annual headwind hcv sale remain forecast
period price patient demand declin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
ogilead market sever single-tablet regimen hiv
next-gener product better long-term
safeti profil led genvoya biktarvi
boost compani market share
ogilead need rapidli convert hiv patient newer
product like genvoya biktarvi avoid
signific hit sale key patent begin
expir
oguidelin aim
improv diagnosi
treatment rate new prophylaxi use provid
strong tailwind growth hiv
owith approv sovaldi harvoni gilead
market leader all-or hepat treatment
none gilead competitor nucleotid
analog make billion acquisit
opric pressur reduc willing pay
conveni could weigh gilead growth atripla
becom formid gener competitor
gilead newer hiv product compet
hepat regimen give pbm abil
ohcv patient demand plummet visibl
long-term demand price low
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
gilead held billion cash market secur
billion debt end gilead
continu rais debt rel low rate assum
blend interest rate includ
billion debt term loan support octob
acquisit kite pharma gilead use cash fund
aggress share repurchas billion
rel new dividend gilead hiv hcv busi
also gener stellar cash flow despit declin hcv
sale gilead gener around billion free cash
flow annual expect gilead use
cash futur acquisit particularli tax reform
allow repatri oversea cash note share
repurchas dial back significantli fund
dividend growth acquisit
increas competit price pressur hiv
hepat market risk gilead global price
pressur consolid pharmaci benefit manag
could reduc gilead abil charg price premium
new drug extend patent protect gilead newest
hiv product perceiv offer significantli
improv safeti efficaci versu older hiv product
larg portion sale foundat could risk
patent gilead top market hiv product expir
firm need see signific switch
newer product like biktarvi counter neg
impact gener competitor estim
gilead -base hiv sale volum
repres govern purchas higher rebat
sale implement escal
overal healthcar cost tight budget could lead
continu elev price pressur
europ gilead also paid signific premium acquir
myogen failur darusentan put pressur
letairi make deal accret billion
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
pharmasset acquisit foundat gilead hcv
franchis allow gilead gener billion
hcv revenu alon gilead hcv busi
declin steepli sinc competit allow
like express script
aggress negoti price gilead continu
compet price hiv express script could exclud
newer hiv product formulari safe
effect competit -- like gilead atripla
regimen could also put pressur price payer could
get creativ offer financi incent patient
take new combin patent expir
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
repres date owner name posit common share held report holder issuer
american fund invmt co amer
new york mellon corp
share
fund
share
fund
stewardship rate gilead standard firm
undergo manag transit await detail
chang strategi perform previous
applaud gilead moat-build
strategi good alloc capit superior board
independ qualif
gilead year massiv manag turnov
think hire roch daniel day
new chairman ceo effect march add
stabil concern firm might still lack
scientif expertis need guid accret merger
signific turnov give firm opportun fresh
manag team enter time massiv revenu
headwind hcv franchis abat think
earli assum live prior
martin/milligan team record see blood cancer
immunolog key area futur growth gilead
fit well day prior experi roch
howev gilead current relianc core hiv portfolio
growth put pressur pipelin advanc
abil make strateg sound detail support
strategi day roch year
ceo roch pharmaceut divis sinc
departur pascal soriot window
abil make accret deal limit includ
billion acquisit intermun mildli disappoint
gilead ceo john milligan step end
along board chairman former ceo john martin
milligan spent year gilead
ceo role sinc march follow chief scientif
offic norbert bischofberg departur end april
chief medic offic andrew cheng departur
septemb milligan martin
insid gilead board
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
offer divers skill set includ expertis public polici
infecti diseas global health initi like
manag reward progress rather
earn per share gilead heavi billion share
repurchas made valuat
recent share price current fair valu estim
program shrunk significantli sinc presum
gilead save potenti acquisit
gilead made sever acquisit collabor
deal year support infecti
diseas portfolio exampl acquisit triangl
brought emtriva critic compon truvada
firm single-tablet hiv regimen outsid
gilead therapeut area focu acquisit cv
therapeut also wise invest angina drug
ranexa grow strongli addit billion bet
pharmasset -- hepat drug sovaldi --
excel use capit earli judg
billion acquisit kite pharma current
assum deal neutral long-term roic upsid
possibl yescarta uptak faster expect kite
pipelin beyond yescarta prove lucr downsid
exist car-t therapi prove safer
treatment modal like bispecif offer similar
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
rais gilead fve biktarvi filgotinib
gilead report strong second-quart result ahead
estim launch hiv combin regimen
biktarvi drive perform gilead increas
guidanc product sale
billion larg biktarvi strength estim
low end prior guidanc billion
significantli rais fair valu estim
account rapid shift biktarvi older
hiv medicin well grow confid
potenti filgotinib rheumatoid arthriti gilead
increasingli face gener version oldest hiv
medicin next year think signific
improv newer version well extens
new area like oncolog immunolog support
stabl wide moat share appear incorpor overli
pessimist long-term evolut firm pipelin
highlight hiv filgotinib gilead biggest growth
opportun biktarvi continu beat estim
gilead rapidli gain switch older hiv
medicin competitor like glaxo
increas biktarvi estim remain somewhat
cautiou long-term threat new two-drug
regimen like glaxo dovato approv
 april list price biktarvi
highlight opportun hiv drug descovi pre-
exposur prophylaxi prep approv
indic expect fourth quarter drug
abl show efficaci benefit gilead older drug
truvada see prep sale today roughli billion
annual stronger safeti profil recent data
descoy potenc like enough gilead push
patient convert descovi despit truvada gener
potenti long-act inject hiv regimen
uncertain gilead could potent capsid inhibitor
use regimen combin dose
interv still determin
gilead biggest recent news confirm firm
plan file approv filgotinib rheumatoid arthriti
 europ base encourag
discuss fda multipl posit phase
readout increas sale forecast potenti
billion peak probabl approv
addit think gilead decis expand
collabor galapago make good strateg sens
gilead gain access galapago research platform
therapi clinic trial right outsid europ
expand gilead inflamm pipelin includ
phase idiopath pulmonari fibrosi
phase osteoarthr give firm
base european research expand galapago
deal cost billion up-front payment
billion equiti invest make much
dent gilead cash balanc stood billion
end second quarter deal close third
quarter expect deal inflamm
oncolog area addit gilead recent hire
christi shaw head kite cell therapi divis
experi lilli novarti allow gilead form
clearer vision oncolog strategi come
month although wari yescarta long-term sale
potenti crowd lymphoma market
gilead exposur potenti drug price reform
 think firm particularli expos
medicar part reform discuss rebat rule
dead suppli chain benefit drug firm pressur
gilead high exposur part
estim total sale firm disclos
sale part howev gilead reli larg
price increas sale growth inflat cap could
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
minim impact although greater catastroph phase
coverag respons could weigh firm
senat financ committe chairman chuck grassley
democrat rank member ron wyden post
prescript drug price reduct act tuesday
although final bill need proceed
mark-up thursday get major vote full
committe could see chang proce
senat floor vote like mean bipartisan
agreement reach prior post share price
drug firm larg unmov news
think progress senat make less like
sever hh rule intern price benchmark
medicar part implement also mean
increasingli like legisl could hold price
increas extent make fair valu
estim chang news continu watch
updat senat follow thursday mark-up
hous like propos legisl
septemb caution possibl bipartisan
bill could pass senat fail hous
progress democrat will compromis
certain issu exampl medicar part direct
negoti includ pdpra regardless
expect overhang drug stock next sever
month drug price overhaul remain key topic
washington result continu see industri
under-valued despit strong product increasingli
overal propos pdpra similar
discuss recent analysi rebat rule dead
signific benefit pdpra compar
rebat rule cost congression budget offic
cbo estim rebat rule would result
billion extra feder spend year
assum current rebat withheld contrast
cbo estim pdpra would save taxpay
billion year billion save
medicaid mostli increas maximum rebat
billion save medicar within medicar
save larg split part redesign
billion inflation-reb polici billion
would forc drugmak pay addit rebat drug
medicar part part price increas
exceed inflat cpi-u roughli annual
addit two medicar polici would help
beneficiari lower pocket cost premium
total billion year cbo also assum
inflation-reb provis would reduc drug cost
patient privat insur part redesign
would substanti effect patient
think unclear impact pdpra could
patient cover privat insur drugmak could
continu rais price privat market simpli pay
addit rebat necessari medicar
among highest-profil provis pdpra
propos cap medicar part part price increas
inflationari level begin excess price
increas would need return medicar form
rebat part expect larg
impact even firm high exposur channel
biggest drug program take
larg price increas reimburs system alreadi
discourag instead reli high launch price
profit exampl among top drug medicar
part spend accord medicar drug
spend dashboard one saw averag annual price
increas
neulasta newer blockbust bristol opdivo
merck keytruda top annual price
increas part expect could
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
drug higher list price increas could
impact dashboard spend data indic averag
annual price increas top drug around
rebat rule dead suppli chain benefit drug firm
pressur estim drug firm exposur
anoth key part pdpra drug manufactur
perspect medicar part redesign could
implement would hit firm
expens drug hardest chang would cap out-
of-pocket cost previous patient paid drug cost
catastroph phase limit
patient enter catastroph coverag phase drug
firm would hook drug cost
elimin current coverag gap discount drug firm
pay cost coverag gap introduc
new respons higher spend level
discuss recent research see firm like gilead
hepat hiv treatment bristol/celgen cancer
therapi revlimid potenti expos peer
gilead return growth least temporarili
maintain per share fair valu estim
gilead follow solid first-quart result
encourag first earn call new ceo daniel day
overal expect gilead focu defend hiv
franchis allow kite innov separ oncolog
cell therapi busi unit maxim potenti launch
immunolog drug filgotinib partner nash
continu test new combin regimen total revenu
grew first quarter first quarter year-over-
year growth three year hiv growth
yescarta launch abl counter declin
hepat revenu top-lin growth like dip
neg year gilead continu fight
hepat declin also lose cardiopulmonari drug
letairi ranexa gener competit think share
incorpor overli pessimist long-term evolut
firm pipelin continu view firm hiv
hcv portfolio well emerg oncolog
immunolog pipelin support stabl wide moat
hiv sale declin sequenti million
headwind due inventori drawdown payer mix
biktarvi launch continu impress rate
million sale quarter solidifi rank
top hiv treatment new switch patient howev
gilead contend new competit
glaxo two-drug regimen dovato approv
april list price biktarvi
gilead steal share glaxo sinc
biktarvi launch expect market share stabil
dovato launch particularli long-term data continu
support efficaci two-drug regimen
gilead truvada continu see strong uptak pre-
exposur prophylaxi therapi total
million patient target market accord cdc
estim march head head studi descovi
versu truvada show descovi non-inferior
efficaci offer better renal bone safeti profil
gilead expect descovi approv indic
fourth quarter see safeti benefit
rel modest leav room gener truvada
compet indic
beyond hiv gilead yescarta sale grow
reimburs improv center train
administ car-t therapi see
competit area encourag gilead decis
move off-the-shelf car-t therapi develop
would like significantli lower cost
product elimin patient wait time
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
gilead promis pipelin therapi filgotinib
produc strong phase data rheumatoid arthriti
file europ year gilead meet
fda determin time file think
testicular safeti data may avail next year
expect gilead hope clean safeti profil
safeti label base recent phase data also see
gilead long-term player nash intern
combin regimen well new partnership
help firm build portfolio albeit long run
wake selonsertib failur two phase studi
nash gilead focus phase studi
combin
remain two advanc drug
candid diseas fxr agonist cilofexor
inhibitor firsocostat data easl april show data
combin small studi improv hepat
steatosi reduc liver fat appar driven firsocostat
well reduc liver stiff reduc fibrosi
improv liver biochemistri driven compound
safeti profil also encourag seriou side
effect deem treatment-rel gilead also recent
expand collabor space gilead novo
nordisk begin proof-of-concept studi combin
novo oral semaglutid cilofexor
firsocostat insitro partnership focus discov
new nash target insitro platform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
